Asthma Clinical Trial
Official title:
Head-Off Environmental Asthma in Louisiana
Verified date | August 30, 2016 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will examine whether exposure to the increased levels of mold and other allergens
in New Orleans post-Hurricane Katrina affect symptoms in children with asthma. It will also
determine if having an asthma counselor (AC) can reduce a child s asthma symptoms in this
setting. An AC helps the families in the study obtain appropriate health care, medicines and
social services for their asthmatic child and instructs them about avoiding allergens and
ridding allergens from the home.
Children between 4 and 12 years of age living in Orleans Parish or surrounding areas impacted
by flooding who have moderate to severe asthma may be eligible for this study.
Parents provide a family medical history and information about the child s asthma symptoms,
medications and medical history. The children undergo the following procedures:
- Medical examination and blood tests
- Spirometry (for children 6 and older) or peak flow (for children under 6) test: For
spirometry, the child wears a nose clip and breathes into a mouthpiece attached to a
machine that measures how fast air moves out of the child s lungs. For the peak flow
meter test, the child blows into a plastic tube after taking a deep breath.
- Allergy skin testing: 24 common allergens are applied to the arm by little pricks or
scratches and the skin is observed for reactions to the allergens.
Study staff visit the participants homes three times during the 1-year study to test for
moisture, mold and other allergens. After the first visit, families are randomly assigned to
one of two groups. Group 1 participants attend two educational group sessions about asthma
and then three individual sessions. An AC visits the home one time during the study to
instruct the family on how to use supplies provided to reduce allergens in the home. Group 2
participants have an individual special teaching meeting with the AC at the end of the study.
After the meeting, the AC visits the home to instruct the family on use of the supplies.
Families are surveyed by phone every 3 months during the study to answer questions about the
child s asthma attacks, medicines used, doctor visits, school days, missed, or work days
missed to care for the child. At the end of the study, the child has a final medical
examination, blood test, and breathing test.
Status | Completed |
Enrollment | 200 |
Est. completion date | August 30, 2016 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 4 Years to 12 Years |
Eligibility |
- INCLUSION CRITERIA: A child will be included in the HEAL intervention study if he or she: 1. Is a male or female child four to twelve years old, inclusive, at the time of recruitment, living in Orleans Parish or surrounding areas impacted by flooding. 2. Has previously been given a diagnosis of asthma by a healthcare provider and who has symptoms as described below (Criteria 3) for more than one year. 3. Is currently receiving long-term asthma control therapy, as reported at baseline, and either has symptoms consistent with persistent asthma (criterion 3a, see below) or has evidence of uncontrolled disease (criterion 3b); or is not currently receiving long-term asthma control therapy and has symptoms consistent with persistent asthma (criterion 3a) and also has evidence of uncontrolled disease (criterion 3b): 3a. Evidence of persistent asthma as defined by the National Asthma Education and Prevention Program (NAEPP) of the National Heart Lung and Blood Institute Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma (1997), which includes: asthma symptoms 3 or more days per week during the last two weeks, sleep disturbed due to asthma at least 3 times in the past month, or albuterol use (Metered Dose Inhaler or nebulizer) for quick relief at least 8 times in the past two weeks, not including use as a preventive for exercise. 3b. Evidence of uncontrolled disease as defined by at least one of the following additional criteria: i. One asthma-related unscheduled visit to an emergency department (ED), urgent care (UC), or clinic in the previous 12 months. ii. One asthma-related overnight hospitalization in the previous 12 months. iii. One or more bursts of oral corticosteroids or equivalent in the previous 12 months. 4) Has a parent or legal guardian willing to sign the written informed consent prior to initiation into the study. 5) Is willing to sign the assent form, if age appropriate. EXCLUSION CRITERIA: A child will be excluded from the HEAL intervention study if she or he: 1. Is defined as having mild intermittent asthma at baseline evaluation. 2. Has had a life-threatening asthma exacerbation in the last 5 years requiring intubation, mechanical ventilation, or resulting in a hypoxic seizure. 3. Has significant medical illnesses other than asthma such as: any hematologic, endocrine, respiratory (other than asthma) or cardiac condition requiring daily medications; significant neurological disorder requiring daily medications; any clotting disorder; any obvious severe mental retardation that prohibits the child or the child s caregiver from answering questions or following instructions; any autoimmune disease; any immune deficiency; or any other serious medical condition including Juvenile diabetes mellitus, hypo- or hyper- thyroidism, hemophilia, Von Willebrands disease, sickle cell disease, cerebral palsy, rheumatoid arthritis, lupus, psoriasis, hyperimmunoglobulin E syndrome, or diagnosed allergic bronchopulmonary aspergillosis. 4. Has not had a home evaluation completed within 4-6 weeks of the Screening Visit (may be re-screened). 5. Lives with a foster parent. 6. Has caregiver (typically the parent or guardian) who does not have access to a phone. 7. Plans to move out of the recruitment area over the next year. One child from each household will be selected to participate in the study. In the case of multiple eligible children, the youngest child will be included in the study. |
Country | Name | City | State |
---|---|---|---|
United States | Tulane University Health Sciences Center | New Orleans | Louisiana |
Lead Sponsor | Collaborator |
---|---|
National Institute of Environmental Health Sciences (NIEHS) | Merck Childhood Asthma Network (MCAN) |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|